Genflow Biosciences Share Discussion Threads

[m_night10] 12/11/2024 07:21

I reckon with news this can easily finish 5p+ this year. Especially after that massive grant just in.

The IPO was at 8p and was massively oversubscribed, so there's a great opportunity here sub 2p.

[moneymunch] 08/11/2024 08:45

Looks like they already have a Vet Partner in place, and are now awaiting Proof of Concept, before a lucrative game changing licensing deal is announced. Exciting times!!! Gl :-)

Ps given the cutting edge science, Gene Therapy and delivery, and compelling nature of SIRT6's influence and importance in multiple therapeutic actions , diseases and aging, then every chance a Major Pharma could make an early move. In Eric we trust!!! :-)

"There's a very large appetite from the veterinary industry for life extension for our dog companions. Therefore, we'll provide proof of concept. We're starting this very soon, and once this proof of concept is finished, that should trigger an out-licensing deal with our partner in veterinary. "

[moneymunch] 08/11/2024 07:12

OTC Markets Hosts Virtual Investor Presentation with Eric Leire, Founder & CEO of Genflow Biosciences, and Brad Sorensen, Senior Analyst at Zacks SCR

14th October 2024

Eric Leire: Thank you for giving me the opportunity to share my passion for what I consider the most exciting biotech company on the market. Let's start. The session today will be a short presentation, as short as possible, five minutes, just an overall presentation of the company, and it should be followed by a discussion with Brad that will be easier for the audience. As Brad mentioned, we are listed on the London Stock Exchange, and we're trading in the US on OTCQB, so I have to have this forward-looking segment; you are used to it. Let's move to the real presentation of the company. At Genflow, we are a longevity company. We consider longevity both as a problem and an opportunity. It's a problem in spite of the fact that in the last hundred years, we have gained a second life, moving from 40 years of life expectancy to 80 years.

EL: We are still losing half of this second life fighting against cancer, diabetes, cardiovascular disease, and neurogenerative disease. When you combine this with an aging population and a higher cost of therapy, you can see this is a problem and an unsustainable situation for society. It's a problem, but it's also an opportunity. It's an opportunity because we have started to understand the biological drivers of aging. As we identify those biological drivers of aging, we can use those to identify new targets to better treat age-related diseases. It's also an opportunity because when health agencies recognize aging as a risk factor, and this will happen, and when those agencies regulate the development of anti-aging drugs, it's very likely that we'll see a big move from big pharma and a major wave of acquisition of the few longevity companies.

EL: We use the understanding of the biology of aging to develop new gene therapy based on those genes that regulate aging. Sirtuin 6 is one of that age-related regulator gene that has been identified in multiple species, both in small animals and in humans. In addition, we use a mutation of the Sirtuin 6 that we found only in centenarians. So in some kind of a super Sirtuin 6, that allows people to go to, pass a hundred years age. Genflow is also supported by a fantastic team, both at the management level, at the board level, and at the scientific advisory board, with a longevity expert such as Vera Gorbunova of the University of Rochester or Eric Verdin at the Buck Institute. We're not a one-trick pony. We have a solid pipeline with four different programs. The program is mainly led by MASH, previously known as NASH. MASH is the fibrotic evolution of the fatty liver.

EL: We think we have a good shot at MASH. It's a difficult indication, but based on our preclinical trial results, we still have a very good shot at MASH. Why? Because we act at every step of the disease. We have an activity on the fat deposition, we have an activity on inflammation, on fibrosis, on liver function, and, ultimately also on the risk of cancer. So, a good shot. It's also an interesting indication because it's a very large market opportunity with 36 million people affected by MASH in the world. Also, it's a huge unmet need for those 36 million people affected with MASH. MASH is becoming all over the world as the first cause for liver transplantation. But, the market project is not limited to purely the disease itself MASH. Because of our approach to taking anti-aging drugs and applying them to this specific disease, we open up the door to very likely associated off-label origination benefits on other organs. We have the same market opportunity as Sarcopenia. Sarcopenia is the loss of muscle that you experience when you age.

EL: It's a very bad sign because it increases your risk of cancer, diabetes, and cardiovascular disease. You lose the social links. It's something important with no therapy. So also large market, unmet needs. In addition, we have the Werner syndrome. Werner syndrome is a rare progeria. It's a disease of accelerating aging. It's strategically very important for us because we want to establish as much as possible a pure anti-aging benefit. This is the acid test. If you can delay, stop, or even reverse aging in this population, that's a perfect test for all of us. Finally, the force program is a program we do with dogs. There's a very large appetite from the veterinary industry for life extension for our dog companions. Therefore, we'll provide proof of concept. We're starting this very soon, and once this proof of concept is finished, that should trigger an out-licensing deal with our partner in veterinary. I would like to thank you and move to the Q&A section. Welcome, Brad, to the presentation.

[moneymunch] 07/11/2024 09:49

Eric did say in his recent iterview they had "several " non-dilutive grant applications that were looking very promising. We've had confirmation of the $4m Wallonia grant and so every chance news of another one next. Gla holders, the current bargain low offers tremendous UPside potential, especially commensurate to the lowly market cap of £6.29m and not far off £5m cash in the bank. Plenty more potential positive newsflow stacking UP!!! :-)

[moneymunch] 06/11/2024 08:33

Grabbed around 650k shares this morning at this rockbottom bargain low, one trade for 397k plus shares yet to be listed. Genflow has plenty of cash going forward and their cutting edge science offers exponential UPside potential and there's plenty of potential stellar newsflow to look forward in the coming weeks and months to add significant value. Gla holders;-)

[inaminute] 24/10/2024 17:30

It was just another lazy deramp. They think that something like that is a clever insightful comment

[bri15] 24/10/2024 14:22

Plus the budget isn't until Wednesday so why would everyone sell tomorrow? imbecile.

[bri15] 24/10/2024 14:00

You pay inheritance tax on money received after someone has died and I don't think there's many dead people investing in AIM.

[bri15] 24/10/2024 13:50

Inheritance tax on AIM won't make any difference as most don't make enough to get into the rate for it anyway,so stop been a doommonger.

[bri15] 24/10/2024 13:48

Why have a placing? company has just been awarded more funds, don't you read the RNS, imbecile.

[kingston78] 24/10/2024 12:36

The company will have to raise more funds by a discounted placing.

[luckyabbeygale] 24/10/2024 07:11

Every aim stock will fall tomorrow now the Labour government is adding inheritance tax to them.

[moneymunch] 22/10/2024 18:38

A great interview by Eric on today's news. Gla :-)

[moneymunch] 22/10/2024 12:16

Lol Northeast, if not today then hopefully in the coming days, until the short term blinkered stop handing over their shares so cheaply. Genflow are financially secure and debt free for the foreseeable, and plenty of positive newsflow in the pipeline on their research and development on their cutting-edge science to deliver fair value and more. Gl ;-)

[northeast14] 22/10/2024 10:50

Hopefully it moves this afternoon. Weak hands are out

[moneymunch] 22/10/2024 06:30

Brilliant news, and just the start of Genflow's stellar UPside journey!!! Gla holders ;-)

[molatovkid] 22/10/2024 06:29

great news obviously

[moneymunch] 22/10/2024 06:08

22 October 2024



Genflow Biosciences Plc



Genflow Secures €4 Million Non-Dilutive Financial Support from Wallonia Region for GF-1002 Development



Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease.



The financial support comprises a €1,218,349.44 non-reimbursable research grant, covering 70% of the Company's research costs, and a €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH, funding 55% of the Company's development costs. This funding, when received, is expected to cover three years of Genflow's development program for GF-1002,with the first installment being received as working capital. The Company is committed to securing the necessary funding to cover its share of the project over the next three years.



The securing of such funding marks a significant milestone for Genflow and will enable the Company to accelerate the clinical progress of GF-1002, which represents a novel approach to treating MASH, a condition with limited treatment options. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy.



Dr. Eric Leire, CEO of Genflow, commented: "We are delighted to receive this substantial financial backing from the Wallonia region as it is an important validation of our research and development efforts. It will allow us to further the development of GF-1002 and strengthen our position at the forefront of gene therapy innovation for MASH treatment. We would like to sincerely thank the Wallonia region for its support."



Further updates on the progress of GF-1002 will be provided in due course.

[moneymunch] 17/10/2024 11:27

Looks like someone is loading UP on the cheap...news at anytime!!! Gla holders:-)

[moneymunch] 14/10/2024 16:52

Genflow's recent Sirt6 Research publication could be of great interest to Lilly's UK investment plans. Gla :-)

20/7/24

Conclusions: SIRT6 N308K/A313S overexpression in mature adipocytes ameliorated glucose sensitivity and impacted sympathetic innervation signaling. These findings highlight the importance of targeting SIRT6 enzymatic activities to regulate the co-morbidities associated with obesity.




Funding

This work was supported by GenFlow Bioscience, by the European Commission Horizon 2020 Framework Program (Project 856871”TRANSTEM, to MV) and by grants from the US national Institute of Health, Impetus Grants and Michael Antonov Foundation (to VG).

[moneymunch] 14/10/2024 16:45

Lilly to Invest $364 Million in UK Biotech, Obesity Research
Drugmaker will also study obesity medication rollout in UK

Labour government has tried to attract foreign investment


The UK has aimed to position itself as a life-sciences superpower.

14 October 2024

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use of health-care resources.

The Indianapolis-based drugmaker’s investment includes as much as £204 million to establish a Lilly Gateway Labs location in the UK, according to an emailed statement Monday, giving early-stage biotechs access to Lilly’s expertise, lab space and potential financial investment.

[moneymunch] 10/10/2024 06:20

The Quest for Extended Youth
Bar-Ilan University to host four-day international conference exploring the future of healthy longevity


Newswise — Later this month Bar-Ilan University will host an international conference dedicated to the advancement of research, development and education in the field of healthy longevity. The conference, entitled “Longevity Nation 2024 – Enhancing Research, Development and Education for Healthy Longevity”, will bring together leading voices in longevity research from around the world. It will take place from October 28-31 on the Bar-Ilan University campus in Ramat Gan, Israel.

.......

Notable speakers will include:

Prof. Haim Cohen (Goodman Faculty of Life Sciences, Bar-Ilan University), who is researching the protein SIRT6. In his lab, mice engineered to produce extra SIRT6 don't just live longer – they stay healthier for longer, too. Cohen's research is shedding light on how SIRT6 helps maintain healthy aging, particularly by providing the required energy at old age and slowing aging-related frailty. This work could pave the way for new therapies that boost SIRT6 activity in humans.

Repurposing Old Drugs for New Tricks

Dr. Nir Barzilai (Albert Einstein College of Medicine) focuses on repurposing existing FDA-approved drugs for their potential anti-aging properties. One example is the diabetes drug metformin, which has been shown to provide broader health benefits, and potentially slowing the aging process itself.




.........


Dr Nir Barzilai is also a partner n Genflow's key European Patent. Gl :-)




21 March 2024

Genflow Biosciences Plc

Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.

[moneymunch] 08/10/2024 17:38

Advanced Therapies in Belgium Event on October 15thToday 11:12
Simon Deré

From R&D discovery to early clinical development 💉Meet 2 Bridge Consultancy at 📍 Advanced Therapies📍Dutch Lifescience Conference 📍 BIOFIT 📍

1d

2 Bridge will be attending the Advanced Therapies in Belgium Event on October 15th 📍

Many therapies, especially those originating from academic research, often stumble when it comes to regulatory and CMC requirements. 👉 Let's connect and discuss how we can navigate these challenges together.

We’d love to grab a coffee ☕ and chat about how to successfully translate complex therapies into first-in-human clinical trials.

And don’t miss out—Dominique Van Looveren will be speaking about our work with Genflow Biosciences (LON:GENF) (OTCQB:GENFF).

Genflow Biosciences is a UK based biotech company with R&D facilities 🔬 in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans 🧔 and dogs 🐕 .

Stay tuned for more details on timing ⏲ !

Looking forward to seeing you there!

BioWin MEDVIA Normec

#AdvancedTherapies #ClinicalTrials #RegulatoryAffairs #CMC #2Bridge

[moneymunch] 08/10/2024 17:33

What humans can learn from animals that age better than we do

Vera Gorbunova will share groundbreaking research on the biological mechanisms of aging at the Fralin Biomedical Research Institute at VTC’s next Maury Strauss Distinguished Public Lecture.

....
Gorbunova, a professor and co-director of the University of Rochester’s Aging Research Center, studies longevity and cancer resistance in mammals with extraordinary lifespans. Her lab studies long-lived mammals in hopes of creating interventions to prevent and treat age-related diseases in humans.

She will deliver a talk about the “Mechanisms of Longevity: From Mice to Whales” at the Fralin Biomedical Research Institute at VTC in Roanoke at 5:30 p.m. on Thursday, Oct. 10.

[moneymunch] 04/10/2024 18:58

Well, no idea how the OTC Market works, still showing 52% UP at $0.0423!!!??? Should be interesting what this coming week brings, potential positive newsflow, stacking UP on several fronts. Gla holders...in Eric we trust!!! :-)